Peter Chang
YOU?
Author Swipe
View article: MRD4U: A path to development for personalized liquid biopsy for children with central nervous system tumors
MRD4U: A path to development for personalized liquid biopsy for children with central nervous system tumors Open
These findings demonstrate applicability of our personalized MRD4U assay in early detection of disease recurrence. Unlike non-targeted or tumor-agnostic CSF liquid biopsy approaches, MRD4U leverages patient-specific genomic information to …
View article: Sacituzumab Govitecan Population Pharmacokinetics: Updated Analyses Using <scp>HR</scp>+/<scp>HER2</scp>− Metastatic Breast Cancer Data From the Phase 3 <scp>TROPiCS</scp>‐02 Trial
Sacituzumab Govitecan Population Pharmacokinetics: Updated Analyses Using <span>HR</span>+/<span>HER2</span>− Metastatic Breast Cancer Data From the Phase 3 <span>TROPiCS</span>‐02 Trial Open
Sacituzumab govitecan (SG) is an antibody–drug conjugate composed of a Trop‐2–directed antibody coupled to SN‐38. SG is approved in multiple countries for pretreated metastatic triple‐negative breast cancer (mTNBC) and hormone receptor‐pos…
View article: Population pharmacokinetics and pharmacodynamics of edoxaban in pediatric patients
Population pharmacokinetics and pharmacodynamics of edoxaban in pediatric patients Open
Edoxaban is an orally active inhibitor of activated factor X (FXa). Population pharmacokinetic (PK) and pharmacodynamic (PD) analyses were performed to characterize the PK and PK–PD relationships of edoxaban in pediatric patients to identi…
View article: Characterization of mavacamten pharmacokinetics in patients with hypertrophic cardiomyopathy to inform dose titration
Characterization of mavacamten pharmacokinetics in patients with hypertrophic cardiomyopathy to inform dose titration Open
Mavacamten is a selective, allosteric, reversible cardiac myosin inhibitor that has been developed for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM). A population pharmacokinetic (PopPK) model was d…
View article: Histopathology imaging and clinical data including remission status in pediatric inflammatory bowel disease
Histopathology imaging and clinical data including remission status in pediatric inflammatory bowel disease Open
The incidence of inflammatory bowel disease (IBD) is increasing annually. Children with IBD often suffer significant morbidity due to physical and emotional effects of the disease and treatment. Corticosteroids, often a component of therap…
View article: Bayesian Online Natural Gradient (BONG)
Bayesian Online Natural Gradient (BONG) Open
We propose a novel approach to sequential Bayesian inference based on variational Bayes (VB). The key insight is that, in the online setting, we do not need to add the KL term to regularize to the prior (which comes from the posterior at t…
View article: Dual-comb correlation spectroscopy of thermal light
Dual-comb correlation spectroscopy of thermal light Open
The detection of light of thermal origin is the principal means by which humanity has learned about our world and the cosmos. In optical astronomy, in particular, direct detection of thermal photons and the resolution of their spectra have…
View article: Population Pharmacokinetics of Sacituzumab Govitecan in Patients with Metastatic Triple-Negative Breast Cancer and Other Solid Tumors
Population Pharmacokinetics of Sacituzumab Govitecan in Patients with Metastatic Triple-Negative Breast Cancer and Other Solid Tumors Open
These analyses support the approved SG dosing regimen of 10 mg/kg as intravenous infusion on days 1 and 8 of 21-day cycles and did not identify a need for dose adjustment based on evaluated covariates or disease characteristics.
View article: Postradical prostatectomy prostate‐specific antigen outcomes after 6 versus 18 months of perioperative androgen‐deprivation therapy in men with localized, unfavorable intermediate‐risk or high‐risk prostate cancer: Results of part 2 of a randomized phase 2 trial
Postradical prostatectomy prostate‐specific antigen outcomes after 6 versus 18 months of perioperative androgen‐deprivation therapy in men with localized, unfavorable intermediate‐risk or high‐risk prostate cancer: Results of part 2 of a randomized phase 2 trial Open
Background Patients with localized, unfavorable intermediate–risk and high‐risk prostate cancer have an increased risk of relapse after radical prostatectomy (RP). The authors previously reported on part 1 of this phase 2 trial testing neo…
View article: Patient-reported outcomes before treatment for localized prostate cancer: are there differences among countries? Data from the True North Global Registry
Patient-reported outcomes before treatment for localized prostate cancer: are there differences among countries? Data from the True North Global Registry Open
Introduction Similar Patient-Reported Outcomes (PROs) at diagnosis for localized prostate cancer among countries may indicate that different treatments are recommended to the same profile of patients, regardless the context characteristics…
View article: Hereditary paraganglioma–phaeochromocytoma syndrome: a case of SDHB mutation
Hereditary paraganglioma–phaeochromocytoma syndrome: a case of SDHB mutation Open
Dear Sir, Paragangliomas are neuroendocrine tumours distributed along the paravertebral axis from the base of the skull to the pelvis and are known as phaeochromocytomas when they arise from chromaffin cells of the adrenal medulla. Paragan…
View article: Low-rank extended Kalman filtering for online learning of neural networks from streaming data
Low-rank extended Kalman filtering for online learning of neural networks from streaming data Open
We propose an efficient online approximate Bayesian inference algorithm for estimating the parameters of a nonlinear function from a potentially non-stationary data stream. The method is based on the extended Kalman filter (EKF), but uses …
View article: Methamphetamine use increases the risk of cerebral small vessel disease in young patients with acute ischemic stroke
Methamphetamine use increases the risk of cerebral small vessel disease in young patients with acute ischemic stroke Open
Methamphetamine use causes spikes in blood pressure. Chronic hypertension is a major risk factor for cerebral small vessel disease (cSVD). The aim of this study is to investigate whether methamphetamine use increases the risk of cSVD. Cons…
View article: Data from An Antibody–Drug Conjugate Directed against Lymphocyte Antigen 6 Complex, Locus E (LY6E) Provides Robust Tumor Killing in a Wide Range of Solid Tumor Malignancies
Data from An Antibody–Drug Conjugate Directed against Lymphocyte Antigen 6 Complex, Locus E (LY6E) Provides Robust Tumor Killing in a Wide Range of Solid Tumor Malignancies Open
Purpose: Chemotherapies are limited by a narrow therapeutic index resulting in suboptimal exposure of the tumor to the drug and acquired tumor resistance. One approach to overcome this is through antibody–drug conjugates (ADC) that facilit…
View article: Supplementary Figures S1-4 and Tables S1-6 from An Antibody–Drug Conjugate Directed against Lymphocyte Antigen 6 Complex, Locus E (LY6E) Provides Robust Tumor Killing in a Wide Range of Solid Tumor Malignancies
Supplementary Figures S1-4 and Tables S1-6 from An Antibody–Drug Conjugate Directed against Lymphocyte Antigen 6 Complex, Locus E (LY6E) Provides Robust Tumor Killing in a Wide Range of Solid Tumor Malignancies Open
Supplementary Figures S1-4 and Tables S1-6. Supplementary Figure S1. LY6E is overexpressed in a subset of breast cancers Supplementary Figure S2. LY6E transcript expression in normal human tissues is shown. Supplementary Figure S3. Endocyt…
View article: Supplemental Methods and Figure Legends from An Antibody–Drug Conjugate Directed against Lymphocyte Antigen 6 Complex, Locus E (LY6E) Provides Robust Tumor Killing in a Wide Range of Solid Tumor Malignancies
Supplemental Methods and Figure Legends from An Antibody–Drug Conjugate Directed against Lymphocyte Antigen 6 Complex, Locus E (LY6E) Provides Robust Tumor Killing in a Wide Range of Solid Tumor Malignancies Open
Supplemental Methods and Figure Legends. Supplementary methods to the article as well as figure legends to the supplementary figures and supplementary tables are provided.
View article: Supplementary Figures S1-4 and Tables S1-6 from An Antibody–Drug Conjugate Directed against Lymphocyte Antigen 6 Complex, Locus E (LY6E) Provides Robust Tumor Killing in a Wide Range of Solid Tumor Malignancies
Supplementary Figures S1-4 and Tables S1-6 from An Antibody–Drug Conjugate Directed against Lymphocyte Antigen 6 Complex, Locus E (LY6E) Provides Robust Tumor Killing in a Wide Range of Solid Tumor Malignancies Open
Supplementary Figures S1-4 and Tables S1-6. Supplementary Figure S1. LY6E is overexpressed in a subset of breast cancers Supplementary Figure S2. LY6E transcript expression in normal human tissues is shown. Supplementary Figure S3. Endocyt…
View article: Supplemental Methods and Figure Legends from An Antibody–Drug Conjugate Directed against Lymphocyte Antigen 6 Complex, Locus E (LY6E) Provides Robust Tumor Killing in a Wide Range of Solid Tumor Malignancies
Supplemental Methods and Figure Legends from An Antibody–Drug Conjugate Directed against Lymphocyte Antigen 6 Complex, Locus E (LY6E) Provides Robust Tumor Killing in a Wide Range of Solid Tumor Malignancies Open
Supplemental Methods and Figure Legends. Supplementary methods to the article as well as figure legends to the supplementary figures and supplementary tables are provided.
View article: Data from An Antibody–Drug Conjugate Directed against Lymphocyte Antigen 6 Complex, Locus E (LY6E) Provides Robust Tumor Killing in a Wide Range of Solid Tumor Malignancies
Data from An Antibody–Drug Conjugate Directed against Lymphocyte Antigen 6 Complex, Locus E (LY6E) Provides Robust Tumor Killing in a Wide Range of Solid Tumor Malignancies Open
Purpose: Chemotherapies are limited by a narrow therapeutic index resulting in suboptimal exposure of the tumor to the drug and acquired tumor resistance. One approach to overcome this is through antibody–drug conjugates (ADC) that facilit…
View article: Data from Mammary Tumor Regression Elicited by Wnt Signaling Inhibitor Requires IGFBP5
Data from Mammary Tumor Regression Elicited by Wnt Signaling Inhibitor Requires IGFBP5 Open
Wnt ligand–driven tumor growth is inhibited by the soluble Wnt inhibitor Fzd8CRD, but the mechanism through which this effect is mediated is unknown. In the MMTV-Wnt1 mouse model, regression of mammary tumors by Fzd8CRD treatment coincides…
View article: Supplementary Methods, Figures 1-7 from Mammary Tumor Regression Elicited by Wnt Signaling Inhibitor Requires IGFBP5
Supplementary Methods, Figures 1-7 from Mammary Tumor Regression Elicited by Wnt Signaling Inhibitor Requires IGFBP5 Open
PDF file - 717K
View article: Supplementary Methods, Figures 1-7 from Mammary Tumor Regression Elicited by Wnt Signaling Inhibitor Requires IGFBP5
Supplementary Methods, Figures 1-7 from Mammary Tumor Regression Elicited by Wnt Signaling Inhibitor Requires IGFBP5 Open
PDF file - 717K
View article: Data from Mammary Tumor Regression Elicited by Wnt Signaling Inhibitor Requires IGFBP5
Data from Mammary Tumor Regression Elicited by Wnt Signaling Inhibitor Requires IGFBP5 Open
Wnt ligand–driven tumor growth is inhibited by the soluble Wnt inhibitor Fzd8CRD, but the mechanism through which this effect is mediated is unknown. In the MMTV-Wnt1 mouse model, regression of mammary tumors by Fzd8CRD treatment coincides…
View article: Methamphetamine use increases the risk of cerebral small vessel disease in young patients with acute ischemic stroke
Methamphetamine use increases the risk of cerebral small vessel disease in young patients with acute ischemic stroke Open
Methamphetamine use causes spikes in blood pressure. Chronic hypertension is a major risk factor for cerebral small vessel disease (cSVD). The aim of this study is to investigate whether methamphetamine use increases the risk of cSVD. Cons…
View article: Adjuvant Chemotherapy Plus Radiotherapy versus Chemotherapy Alone for Locally Advanced Bladder Cancer after Radical Cystectomy
Adjuvant Chemotherapy Plus Radiotherapy versus Chemotherapy Alone for Locally Advanced Bladder Cancer after Radical Cystectomy Open
BACKGROUND: Survival with locally advanced bladder cancer (LABC) following radical cystectomy (RC) remains poor. Although adjuvant chemotherapy (AC) is standard of care, one small, randomized trial has suggested a potential survival benefi…